Perlecan and tumor angiogenesis

被引:96
作者
Jiang, XN
Couchman, JR
机构
[1] Univ London Imperial Coll Sci Technol & Med, Div Biomed Sci, Fac Med, London SW7 2AZ, England
[2] Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA
关键词
perlecan; heparan sulfate proteoglycan; tumor angiogenesis; vascular endothelial growth factor; fibroblast growth factor;
D O I
10.1177/002215540305101101
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Perlecan is a major heparan sulfate proteoglycan (HSPG) of basement membranes (BMs) and connective tissues. The core protein of perlecan is divided into five domains based on sequence homology to other known proteins. Commonly, the N-terminal domain I of mammalian perlecan is substituted with three HS chains that can bind a number of matrix molecules, cytokines, and growth factors. Perlecan is essential for metazoan life, as shown by genetic manipulations of nematodes, insects, and mice. There are also known human mutations that can be lethal. In vertebrates, new functions of perlecan emerged with the acquisition of a closed vascular system and skeletal connective tissues. Many of perlecan's functions may be related to the binding and presentation of growth factors to high-affinity tyrosine kinase (TK) receptors. Data are accumulating, as discussed here, that similar growth factor-mediated processes may have unwanted promoting effects on tumor cell proliferation and tumor angiogenesis. Understanding of these attributes at the molecular level may offer opportunities for therapeutic intervention.
引用
收藏
页码:1393 / 1410
页数:18
相关论文
共 209 条
[21]   Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele [J].
Carmeliet, P ;
Ferreira, V ;
Breier, G ;
Pollefeyt, S ;
Kieckens, L ;
Gertsenstein, M ;
Fahrig, M ;
Vandenhoeck, A ;
Harpal, K ;
Eberhardt, C ;
Declercq, C ;
Pawling, J ;
Moons, L ;
Collen, D ;
Risau, W ;
Nagy, A .
NATURE, 1996, 380 (6573) :435-439
[22]  
CHAKRAVARTI S, 1991, MAMMAL GENOMES, V1, P271
[23]  
Chen HJ, 2000, BRIT J CANCER, V82, P1694
[24]   INTERACTIONS BETWEEN THE FLK-1 RECEPTOR, VASCULAR ENDOTHELIAL GROWTH-FACTOR, AND CELL-SURFACE PROTEOGLYCAN IDENTIFIED WITH A SOLUBLE RECEPTOR REAGENT [J].
CHIANG, MK ;
FLANAGAN, JG .
GROWTH FACTORS, 1995, 12 (01) :1-10
[25]   Developmental control of blood cell migration by the Drosophila VEGF pathway [J].
Cho, NK ;
Keyes, L ;
Johnson, E ;
Heller, J ;
Ryner, L ;
Karim, F ;
Krasnow, MA .
CELL, 2002, 108 (06) :865-876
[26]  
Ciruna BG, 1997, DEVELOPMENT, V124, P2829
[27]  
COHEN IR, 1994, CANCER RES, V54, P5771
[28]   VEGF(121), A VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) ISOFORM LACKING HEPARIN-BINDING ABILITY, REQUIRES CELL-SURFACE HEPARAN SULFATES FOR EFFICIENT BINDING TO THE VEGF RECEPTORS OF HUMAN-MELANOMA CELLS [J].
COHEN, T ;
GITAYGOREN, H ;
SHARON, R ;
SHIBUYA, M ;
HALABAN, R ;
LEVI, BZ ;
NEUFELD, G .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (19) :11322-11326
[29]   Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3 [J].
Colvin, JS ;
Bohne, BA ;
Harding, GW ;
McEwen, DG ;
Ornitz, DM .
NATURE GENETICS, 1996, 12 (04) :390-397
[30]   Heparan sulfate proteoglycans in experimental models of diabetes: a role for perlecan in diabetes complications [J].
Conde-Knape, K .
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2001, 17 (06) :412-421